A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GALEN
- 06 Mar 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 06 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 06 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History